Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development

Atropos Health expands its multimodal real-world evidence network, adding OneMedNet data and boosting query speed and cost efficiency for users.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enhanced network coverage unlocks broader clinical insights and streamlined data access across healthcare, life sciences, and technology platforms

PALO ALTO, Calif.--(BUSINESS WIRE)-- Atropos Health, a leader in real-world evidence (RWE) generation from high-quality healthcare data, today announced a significant expansion of its federated Atropos Evidence™ Network. The expansion includes deeper collaborations with Norstella and Arcadia, along with new data partnership agreements with OneMedNet Corporation (Nasdaq: ONMD).

These alliances extend the scope of Atropos Health’s data ecosystem across clinical decision support (CDS), model training, and benchmark development, delivering precision insights to power modern medicine.

Comprising dozens of primary and aggregated data sources, the federated network now covers:

• National Reach: Over 330 million U.S. patients
• Claims Coverage: Scaled open and closed claims
• EHR Integration: 150 million+ patient EHR records, including clinical notes for regulatory-grade RWE applications
• Multimodal Data: Imaging and omics data linked directly to clinical outcomes and mortality datasets
• Privacy-first Linkage: Advanced cross-source linkage leveraging proprietary de-identification technology

This expanded scale powers critical applications across life sciences, health systems, and technology platforms, including:

• RWE and Observational Research Generation: Regulatory-grade studies incorporating clinical notes, omics, and imaging datasets
• Health Economics & Outcomes Research (HEOR): Advanced cost and utilization analyses driving budget impact and economic modeling
• Rapid Commercial Analytics: On-demand market intelligence covering prescription trends, therapy switching, physician behavior, and commercial targeting
• AI & Predictive Model Training: Algorithmic development to identify rare/undiagnosed patient populations and set model performance benchmarks

Through collaborative integrations with Norstella, Arcadia, and OneMedNet, Atropos Evidence Network users can seamlessly move beyond static data retrieval to generate proactive, on-demand evidence and insights in seconds.

“We are moving medicine toward a future where precision evidence guides every healthcare decision, and that requires embedding evidence capabilities directly into the tools researchers and clinicians use every day,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Incorporating de-identified multimodal data into the Atropos Evidence Network provides the deeper clinical context necessary to fuel healthcare innovation.”

Activating Trustworthy Real-World Insights

Integrating Atropos Health tools allows partner platforms to run complex temporal queries up to 50 times faster and 30 times more cost-effectively than traditional data analytics methods. All integrated solutions leverage Atropos Health’s Real World Fitness Score® (RWFS), an automatic grading framework that evaluates data quality and fitness for specific clinical questions to ensure unmatched trust and transparency.

“This partnership perfectly exemplifies our strategy: transforming our unique, Direct from Source, regulatory decision-grade data into long-term subscription collaborations that put our data directly into our partners’ hands — removing the friction that has traditionally slowed access to high-quality Real-World Data,” said Aaron Green, President & CEO of OneMedNet. “Atropos sets the standard for rapid, personalized evidence, and we strengthen the foundational data beneath it, so their customers can move from question to evidence without the usual barriers.”

About Atropos Health

Atropos Health is closing medicine's most consequential gap: actionable insights to inform the vast majority of clinical decisions that are made without evidence. By generating real-world evidence from actual patient outcomes and data, Atropos Health is building the evidence infrastructure that clinicians, life science researchers, and AI platforms need to practice, develop, and inform medicine, grounded in what actually works. Better healthcare is only possible with evidence, and Atropos Health is working to make it available for every patient, in every healthcare decision, every day. Atropos Health does this via GENEVA OS®, the operating system across a robust network of real-world data; Alexandria®, the world’s largest evidence library; and evidence generation tools such as ChatRWD®, Green Button®, and the Atropos Evidence™ Agent.

To learn more about Atropos Health, visit atroposhealth.com or connect through LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260922102002/en/

media@atroposhealth.com

Source: Atropos Health

Key Terms

real-world evidence medical

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

clinical decision support medical

Software tools and information services that give clinicians patient-specific recommendations, alerts, or diagnostic and treatment options at the point of care—like a GPS that suggests routes based on current traffic, but for medical decisions. Investors care because these tools can improve patient outcomes, reduce errors and costs, drive demand for healthcare IT, and face regulatory and reimbursement rules that affect commercial adoption and revenue potential.

health economics & outcomes research medical

Health economics and outcomes research (HEOR) is the field that measures the costs, health effects, and real-world value of medical treatments, devices, and health programs using data, models, and patient-reported outcomes. It matters to investors because HEOR results influence pricing, insurance coverage, and how widely a therapy is adopted—similar to studying a product’s cost-versus-benefit and likely market acceptance before forecasting sales and long-term revenue.

multimodal data technical

Multimodal data is information that combines different types of sources—such as numbers, written reports, photos, audio, and sensor readings—into a single view. For investors it matters because blending these types is like looking at a company with both a microscope and a wide-angle lens: it can reveal risks, trends, or opportunities that a single type of data would miss, improving decision-making, forecasting, and due diligence.

de-identification technology technical

Tools and methods that remove or obscure personal identifiers from datasets so individuals cannot be readily recognized or re-identified; examples include masking, hashing, aggregation, and statistical techniques validated against re-identification risk. This matters to investors because it affects a company’s ability to use and sell health or customer data, its regulatory compliance and legal exposure, and the commercial value of data assets—similar to blurring faces in a photo so the image can be shared safely.